Immunicom

1 known investors

Immunicom is a biotech company developing immunotherapies based on its Immunopheresis platform, a blood-filtering device that works external to the body to treat cancer and inflammatory, cardiovascular, renal, and autoimmune diseases. Its initial focus is immuno-oncology, with CE Mark approval in Europe for advanced triple-negative breast cancer and multiple ongoing clinical trials.